The Urologic clinics of North America
-
The classification of clinical disease states within advanced prostate cancer is set apart from other solid tumors largely through measurement of prostate-specific antigen in the blood. This testing has allowed the distinction between the castration-sensitive and the castration-resistant states, to complement radiographic distinction within advanced prostate cancer. ⋯ Currently used clinical classifications have limitations and continue to evolve. The authors define the current disease states and discuss implications for prognosis and treatment decisions, as well as the limitations of existing classifications and emerging discoveries.
-
Urol. Clin. North Am. · Nov 2012
The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
This article reviews the initial experience with chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) and outlines some of the ongoing clinical trials in this area. In addition, the authors outline current knowledge on outcomes of patients treated with taxane-based chemotherapy on retrospective analysis of randomized trials. These data are intended to provide physicians and patients with a general idea on the outcomes of men with mCRPC that may facilitate clinical decisions as well as the design and evaluation of clinical trials.